Bertram Glass
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Bertram Glass has a total of 82 co-authors. Here are the top co-authors by number of shared publications:
- Anna Sureda
Clinical Hematology Department, Institut Català d’Oncologia-Hospitalet, Institut d’Investigació Biomèdica de Bellvitge (IDIBELL), University of Barcelona, Barcelona, Spain
24 shared publications - Nicolaus Kröger
University Hospital Eppendorf, Hamburg, Germany
24 shared publications - Peter Dreger
Department Medicine V, University of Heidelberg, Heidelberg, Germany
24 shared publications - Ana Nunes
Kite, a Gilead Company, Santa Monica, CA
23 shared publications - Anna Ossami Saidy
Department of Hematology and Cell Therapy Helios Klinikum Berlin‐Buch Berlin Germany
23 shared publications - Ariane Boumendil
European Society for Blood and Marrow Transplantation Lymphoma Working Party, Paris, France
23 shared publications
Latest Publications
- Open Access
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (19) , 1767-1773
Circulating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
- 1 July 2026
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 44 (19) , 1767-1773
Open AccessCirculating Tumor DNA Assessment of Disease Response in Large B-Cell Lymphoma: Lisocabtagene Maraleucel Versus Autologous Stem Cell Transplantation Standard Therapy
We report correlative circulating tumor DNA (ctDNA) analyses from TRANSFORM (ClinicalTrials.gov identifier: NCT03575351 ) evaluating lisocabtagene maraleucel (liso-cel) versus standard of care (salvage immunochemotherapy, high-dose chemotherapy, autologous stem cell transplantation [ASCT]) in second-line large B-cell lymphoma (LBCL). ctDNA association with efficacy was investigated at predefined time points (random assignment, day 43, day 64, and day 126 [3 months after liso-cel, approximately 2 months after ASCT]) for 136 patients using ultrasensitive PhasED-Seq. ctDNA clearance (measurable residual disease [MRD] neg ) predicted longer event-free survival (EFS) at all time points in both arms, with significantly more liso-cel–treated patients achieving MRD neg . Liso-cel demonstrated superior outcomes versus ASCT, including longer EFS, progression-free survival (PFS), and duration of response among patients in complete response (CR) and MRD neg . ctDNA re-emergence in patients with CR after ASCT confirmed its potential in predicting relapse. MRD neg remained significantly associated with EFS after adjusting for positron emission tomography (PET) response, while interaction testing revealed a significant interaction between PET status and treatment arm for EFS. Liso-cel achieved deeper, more durable molecular clearance by ctDNA, consistent with superior EFS and PFS versus ASCT for second-line LBCL treatment. ctDNA-MRD provided prognostic value beyond PET, supporting its role as a complementary biomarker for treatment response and relapse prediction.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for PFS adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Overall survival (OS) and progression-free survival (PFS) in the unmatched alloHCT cohort based on response status before alloHCT.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cox regression analysis of different treatments for OS adjusting for baseline characteristics (ZUMA-2: n = 64, alloHCT: n = 272)
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S4 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Comparison of ZUMA-2 and alloHCT population for Overall survival (OS), Progression-free survival (PFS), Non-relapse mortality (NRM) and incidence of relapse (IR) in unmatched cohorts.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Flow chart presenting inclusion and exclusion of patients used for final propensity score-matched analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Figure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessFigure S3 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Density plots for each covariate used for propensity score matching before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S6 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Acute and chronic Graft-versus-host-disease in the total alloHCT cohort based on full case analysis.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Characteristics of transplant procedure in alloHCT cohort before and after matching.
- Open Access
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Table S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).
- 17 June 2026
- Published by American Association for Cancer Research (AACR)
Open AccessTable S5 from Brexucabtagene Autoleucel versus Allogeneic Hematopoietic Cell Transplantation in Relapsed and Refractory Mantle Cell Lymphoma
Multivariate cause-specific hazard regression analysis of different treatments for IR in a competing risk setting adjusting for baseline characteristics (full case analysis, ZUMA-2: n = 64, alloHCT: n = 250).